Bradsher Neal C
Company insiders · Director · 10% owner · Lineage Cell Therapeutics, Inc.
- Reported transaction lines
- 4
- Buy lines
- 4
- Sell lines
- 0
Filing activity by month
Original filing lines in up to 12 months with activity.
- 2026-114
Frequently disclosed stocks
Disclosure history
| Reporting investor | Security | Activity | Transaction / period | Filed | Reported amount | Source |
|---|---|---|---|---|---|---|
Joint filing · 3 reporting ownersLineage Cell Therapeutics, Inc. | LCTX Lineage Cell Therapeutics, Inc. | BuyFiling detailsSEC transaction code P Common Shares · Indirect ownership · See Footnote · Reported balance after transaction: 50560992 · SEC code covers open-market or private transactions · The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. | 2026-11-17 | 2026-11-19 | ≈ $0.00 0 shares/units | SEC 4 |
Joint filing · 3 reporting ownersLineage Cell Therapeutics, Inc. | LCTX Lineage Cell Therapeutics, Inc. | BuyFiling detailsSEC transaction code P Common Shares · Direct ownership · Reported balance after transaction: 50560992 · SEC code covers open-market or private transactions · The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed beneficially owned by Broadwood Capital, Inc. as General Partner of Broadwood Partners and Neal C. Bradsher as President of Broadwood Capital, Inc. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of his or its pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. | 2026-11-17 | 2026-11-19 | ≈ $770,700.00 1,000,000 shares/units | SEC 4 |
Joint filing · 3 reporting ownersInsight Molecular Diagnostics Inc. | IMDX Insight Molecular Diagnostics Inc. | BuyFiling detailsSEC transaction code P Common Stock, no par value · Indirect ownership · Footnote · Reported balance after transaction: 16113455 · SEC code covers open-market or private transactions · The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. | 2026-11-17 | 2026-11-19 | ≈ $0.00 0 shares/units | SEC 4 |
Joint filing · 3 reporting ownersInsight Molecular Diagnostics Inc. | IMDX Insight Molecular Diagnostics Inc. | BuyFiling detailsSEC transaction code P Common Stock, no par value · Direct ownership · Reported balance after transaction: 16113455 · SEC code covers open-market or private transactions · On November 17, 2026, Broadwood Partners purchased 3,428,571 shares of Common Stock, no par value (the "Common Shares"), of Insight Molecular Diagnostics Inc. (the "Issuer") from the Issuer in an underwritten public offering for a total purchase price of $5,999,999.25, or $1.75 per Common Share. · The reported securities are directly owned by Broadwood Partners, L.P. ("Broadwood Partners") and may be deemed to be beneficially owned by each of: (i) Broadwood Capital, Inc. ("Broadwood Capital"), as General Partner of Broadwood Partners; and (ii) Neal C. Bradsher, as President of Broadwood Capital. Each Reporting Person disclaims beneficial ownership of the reported securities except to the extent of its or his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Person is the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. | 2026-11-17 | 2026-11-19 | ≈ $5,999,999.25 3,428,571 shares/units | SEC 4 |
Counts describe original filing lines in BriefStock’s coverage. Later amendments can correct or supplement them. Check the original filing for ownership and transaction details.